43 withdrawn. 43 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 43 | Withdrawn 43 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Sevoflurane and Desflurane on Heme Oxygenase-1 Expression in Elective Cholecystectomy Sevoflurane Group, Desflurane Group - Cholecystitis, Chronic | Phase 4 | Withdrawn | Kocaeli City Hospital | 2025-06-01 | 2025-02-05 | |
| IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator - COPD | Phase 4 | Withdrawn | AstraZeneca | 2024-01-19 | 2024-02-01 | |
| A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema RYMPHYSIA, Another Available A1PI - Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency | Phase 4 | Withdrawn | Takeda | 2024-01-01 | 2023-05-06 | |
| TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol High-intensity smoking cessation intervention, Low-intensity smoking cessation intervention - Chronic Obstructive Pulmonary Disease, Smoking Cessation | Phase 4 | Withdrawn | Pradeesh Sivapalan | 2023-07-01 | 2023-02-23 | |
| Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes Control, Albuterol - Asthma in Children, Dyspnea; Asthmatic | Phase 4 | Withdrawn | Ohio State University | 2023-07-01 | 2023-11-07 | |
| Triple vs High Dose Inhaled CORticosteroids To compare in both treatment arms the percentage of patients controlled at week 52. - Asthma | Phase 4 | Withdrawn | Galaxia Empírica | 2023-06-01 | 2025-09-04 | |
| TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg, Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg - COPD | Phase 4 | Withdrawn | Chiesi Farmaceutici S.p.A. | 2021-10-04 | 2022-02-03 | |
| ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study ARALAST NP - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 4 | Withdrawn | Shire | 2021-03-08 | 2020-09-14 | |
| VX-770 for the Treatment of Chronic Bronchitis Ivacaftor (VX-770) - Chronic Bronchitis | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2020-01-01 | 2022-02-17 | |
| Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Fasenra, 30 Mg/mL Subcutaneous Solution - ABPA, Severe Asthma | Phase 4 | Withdrawn | Baylor Research Institute | 2019-12-23 | 2022-02-01 | |
| Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) In Check Dial test - Chronic Obstructive Pulmonary Disease | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2019-09-25 | 2022-08-30 | |
| Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol - Pulmonary Disease, Chronic Obstructive | Phase 4 | Withdrawn | GlaxoSmithKline | 2019-06-27 | 2020-04-22 | |
| Betadine Pleurodesis Via Tunneled Pleural Catheters Povidone-Iodine - Pleural Effusion, Pleurodesis | Phase 4 | Withdrawn | Yale University | 2018-07-01 | 2019-01-11 | |
| The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol - Asthma | Phase 4 | Withdrawn | GlaxoSmithKline | 2018-03-07 | 2018-01-29 | |
| To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease Aclidinium bromide/formoterol fumarate combination, Standard of Care - Chronic Obstructive Pulmonary Disease | Phase 4 | Withdrawn | AstraZeneca | 2017-12-04 | 2017-07-02 | |
| Macitentan in the Treatment of Organ Rejection After Lung Transplantation macitentan, placebo (for macitentan) - Lung Transplant Rejection | Phase 4 | Withdrawn | University of California, Los Angeles | 2016-09-01 | 2020-12-11 | |
| Magnesium Sulfate to Prevent Hospitalisation of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Magnesium Sulfate, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 4 | Withdrawn | Hôpital de Verdun | 2016-09-01 | 2018-02-22 | |
| Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD IN-DEX 1.0 mcg/kg, intranasal saline, IN-DEX 1.5 mcg/kg, intranasal saline, Placebo - Saline - COPD | Phase 4 | Withdrawn | Dayton VA Medical Center | 2016-08-01 | 2018-07-31 | |
| Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD Spiolto® Respimat® (Tiotropium / Olodaterol) - COPD | Phase 4 | Withdrawn | RWTH Aachen University | 2016-08-01 | 2022-10-27 | |
| Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children Beclomethasone, Beclomethasone and Salbutamol, Placebo - Wheeze | Phase 4 | Withdrawn | University of Calgary | 2016-04-01 | 2016-11-15 |
Showing 20 of 43. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (24) · Asthma (11) · Bronchiolitis Obliterans Syndrome (5) · Bronchitis, Chronic (3) · Cough (2) · Dyspnea (2) · Emergencies (2) · Motor Activity (2) · Respiratory Sounds (2) · alpha 1-Antitrypsin Deficiency (2) · Airway Obstruction (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bites and Stings (1) · Bronchiolitis Obliterans (1)
Lung Diseases (43) · Respiratory Tract Diseases (43) · Pathological Conditions, Signs and Symptoms (34) · Pathologic Processes (29) · Disease Attributes (28) · Chronic Disease (27) · Bronchial Diseases (20) · Immune System Diseases (16) · Hypersensitivity (11) · Hypersensitivity, Immediate (11) · Respiratory Hypersensitivity (11) · Bronchitis (8) · Signs and Symptoms (7) · Bronchiolitis (6)
Formoterol Fumarate (5) · Albuterol (4) · Beclomethasone (3) · Budesonide (3) · Tiotropium Bromide (3) · fluticasone furoate (3) · Glycopyrrolate (2) · alpha 1-Antitrypsin (2) · indacaterol (2) · Azithromycin (1) · Carvedilol (1) · Cellulose (1) · Cholecalciferol (1) · Dexmedetomidine (1) · Doxycycline (1)
Novartis Pharmaceuticals (4) · GlaxoSmithKline (3) · AstraZeneca (2) · Imperial College London (2) · University of Alabama at Birmingham (2) · University of California, Los Angeles (2) · Baylor Research Institute (1) · CPL Associates (1) · CSA Medical, Inc. (1) · Chiesi Farmaceutici S.p.A. (1) · Dayton VA Medical Center (1) · Galaxia Empírica (1) · Hull University Teaching Hospitals NHS Trust (1) · Hôpital de Verdun (1) · Jorgen Vestbo (1)
United States (11) · United Kingdom (5) · Denmark (4) · Canada (2) · Turkey (Türkiye) (2) · Australia (1) · Belgium (1) · Germany (1) · Netherlands (1) · Spain (1)
Alyn H Morice, FRCP (1) · An Mariman, MD (1) · Ann E Tilley, MD (1) · Anna Ribera (1) · Anne Boyter, PhD (1) · Brian J Lipworth, MBchB (1) · Brian Lipworth, MD (1) · Catherine Jackson, MD (1) · Court Pedersen, MD (1) · Darcy Marciniuk, MD (1) · David J Ross, MD (1)
PMID 11377644, PMID 15539711, PMID 15955146, PMID 16899830, PMID 18569763, PMID 19194768, PMID 19357145, PMID 19801582, PMID 20335292, PMID 20843247, PMID 21621992, PMID 23649439, PMID 24524926, PMID 24729698, PMID 25176970, PMID 25253795, PMID 26362660, PMID 26414484, PMID 26964078, PMID 27545342, PMID 29377409, PMID 31166007, PMID 32825845, PMID 33027187, PMID 34611902
2008 (1), 2019 (1)